GLP-1 Peptide Atlas, by Delfa

← Trials/Trial dossier/NCT03479762

Completed

In Market Utilisation of Liraglutide Used for Weight Management in the UK: a Study in the CPRD Primary Care Database

Lead sponsor

Novo Nordisk A/S

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

105

actual

Study population

Obesity / overweight

Key I/E criterion

—

Primary endpoints

•BMI above or equal to 30 kg/m^2 (Saxenda® only)•BMI above or equal to 27 kg/m^2 and below 30 kg/m^2•BMI above or equal to 27 kg/m^2 and less than 30 kg/m^2

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT03479762

Org study IDNN8022-4246

Secondary IDEUPAS23369EU PAS Register

Secondary IDU1111-1185-3276WHO

Timeline

Milestones

Study first posted2018-03-27actual

Study start2018-04-20actual

Primary completion2022-09-12actual

Study completion2022-09-12actual

Last update posted2022-11-25actual

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

SexAll

Healthy volunteersNot accepted

Sampling methodNon probability sample

Study population text

Patients in the CPRD primary care database who have been prescribed liraglutide after the UK launch of Saxenda® (and have no liraglutide prescriptions in the previous 12 months)

Inclusion criteria

-New initiators of liraglutide (unbranded, or branded prescription, i.e. Saxenda® or Victoza®), who have no liraglutide prescriptions in the twelve months prior to index date (time of first prescription). Patients must be research standard (registered as "acceptable" in the database) with at least one year of up-to-standard registration prior to their index date

Exclusion criteria

-Not applicable

Endpoints (20)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Safety / tolerability / PK

Weight & body composition

Other (unclassified)

Other clinical outcomes

Weight & body composition

7 endpoints

Primary/protocol endpoint

Number of patients with a BMI above or equal to 30 kg/m^2 (Saxenda® only)

Time frame:Less than 6 months before the date of the first prescription

threshold achievement, descriptive

Primary/protocol endpoint

Number of patients with a BMI above or equal to 27 kg/m^2 and below 30 kg/m^2 and 1 or more comorbidities (Saxenda® only)

Time frame:Less than 6 months before the date of the first prescription

threshold achievement, descriptive

Primary/protocol endpoint

Number of patients with a BMI above or equal to 27 kg/m^2 and less than 30 kg/m^2 and no comorbidities (Saxenda® only)

Time frame:Less than 6 months before the first prescription

threshold achievement, descriptive

Primary/protocol endpoint

Number of patients with BMI below 27 kg/m^2 (Saxenda® only)

Time frame:Less than 6 months before the first prescription

threshold achievement, improvement

Primary/protocol endpoint

Number of patients with less than 5% weight loss and continuing treatment (Saxenda® only)

Time frame:Week 0 (first prescription) to week 16; week 24

≥5% weight-loss responders

threshold achievement, improvement

Primary/protocol endpoint

Mean weight loss in patients not treated according to stopping rule (Saxenda® only)

Time frame:Week 0 (first prescription) to week 16; week 24

change from baseline, improvement

Primary/protocol endpoint

Number of patients with at least 5% weight loss and continuing treatment (Saxenda® only)

Time frame:Week 16 - week 24

≥5% weight-loss responders

threshold achievement, improvement

Safety / tolerability / PK

9 endpoints

Primary/protocol endpoint/low confidence

Number of patients with a BMI not measured (Saxenda® only)

Time frame:Less than 6 months before the first prescription

descriptive

Secondary/protocol endpoint

Number of initiators with other GLP-1 receptor agonists prescribed during continued treatment with Saxenda® (Saxenda® only)

Time frame:From date of first prescription until 24 months

event count, descriptive

Secondary/protocol endpoint

Number of patients who have reached 3.0 mg (Saxenda® only)

Time frame:12 weeks from time of first prescription

descriptive

Secondary/protocol endpoint

Number of patients with a treatment duration of 0-6 months (Saxenda® only)

Time frame:Month 6

descriptive

Secondary/protocol endpoint

Number of patients with a treatment duration of 7-12 months (Saxenda® only)

Time frame:Month 12

descriptive

Secondary/protocol endpoint

Number of patients with a treatment duration of 13-18 months (Saxenda® only)

Time frame:Month 18

descriptive

Secondary/protocol endpoint

Number of patients with a treatment duration of 19-24 months (Saxenda® only)

Time frame:Month 24

descriptive

Secondary/protocol endpoint

Number of patients with a treatment duration of 25-36 months (Saxenda® only)

Time frame:Month 36

descriptive

Secondary/protocol endpoint

Number of patients with ongoing treatment (current users) (Saxenda® only)

Time frame:Month 60

descriptive

Other clinical outcomes

1 endpoint

Secondary/protocol endpoint

Number of initiators with other products for weight management prescribed during continued treatment with Saxenda® (Saxenda® only)

Time frame:From date of first prescription until 24 months

event count, descriptive

Other (unclassified)

3 endpoints

Secondary/protocol endpoint/low confidence

Number of patients fulfilling at least one of the following: 1) a prescription interval corresponding to a daily dose of 3.0 mg, 2) dose information of 3.0 mg per day, or 3) indication of weight management (Victoza® only)

Time frame:Within 4-12 weeks from the date of the first prescription

descriptive

Secondary/protocol endpoint/low confidence

Number of patients with a treatment duration of 37-48 months (Saxenda® only)

Time frame:Month 48

descriptive

Secondary/protocol endpoint/low confidence

Number of patients with a treatment duration of 49-60 months (Saxenda® only)

Time frame:Month 60

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.